newswire, breaking biotechnology and pharma news

Tuesday, November 16, 2010

Investor Video Airing for BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) November 20th

BioSante Pharmaceutical’s President and CEO to be featured on WallStreetCast
on ‘Fox Business with Steve Crowley’, Saturday at 1 pm EST

Point Roberts, WA, LINCOLNSHIRE, Ill –November 16, 2010 ( Newswire) announces to interested biotech and pharmaceutical investors following
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) that the company will be featured in an
upcoming video segment November 20th.

Saturdays airing will feature Mr. Stephen Simes, President and CEO of BioSante, discussing
BioSante’s lead products, including LibiGel®, with host Steve Crowley.

For interested investors looking to watch BioSante’s segment, the show will be aired on
WallStreetCast on Fox Business on Saturday, November 20th at 1 PM EST

Investors can also go to the Money Channel at, to find times aired
and to learn more about Steve Crowley and his interviews with top companies.

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) was also recently interviewed on in a Q&A format. Stephen M. Simes, President and CEO of BPAX Discusses
LibiGel (Testosterone Gel) in Phase III and GVAX Pancreas Vaccine in Phase II. The transcript is
available in full at:

The company was also featured in a recent Investor Spotlight on and its
syndicated partner sites:

BioSante Pharmaceuticals (NASDAQ: BPAX) Lead Product LibiGel® - testosterone gel for
the treatment of female sexual dysfunction

Market for LibiGel® has wide potential with predictions ranging from about $2.0 billion up to $5

Point Roberts, WA, LINCOLNSHIRE, Ill - November 9, 2010 ( Newswire,)
Investor ideas and its biotech portal present a company and product spotlight for BioSante
Pharmaceuticals, Inc. (NASDAQ: BPAX) lead product LibiGel®.

Investors following biotech and pharmaceutical stocks can take an in-depth look at the current
status of LibiGel®, the clinical data, the market drivers and opportunities within the company
product brochure, recent news links and a recent Q&A with Mr. Stephen M. Simes, President and
CEO discussing LibiGel.

Highlights from the LibiGel Brochure:

Read the Full Brochure at:

LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who
suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-
blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal
women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-
approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through
the skin after applying a once-daily pea-sized topical application on the upper arm that delivers

testosterone to the bloodstream evenly over time.

Full Article:

Research more biotech stocks at the Biotech stocks Directory: http://

About is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. is
known for its comprehensive stock directories in each sector and sector specific newswires.

About our Biotech investor portal: is a global meeting place for investors and industry following the
sector, within Global visitors use the site daily to research the latest news,
articles, audio, research reports and our stock directories.

If you have any questions regarding information in this press release please contact the company
listed in the press release.

Contact BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953

For Media:
Alan Zachary
(312) 944-6784 ext. 316
The content from the investor Fact sheet and opinions from http:// are not the opinion of or related websites.

The following news is paid for by BPAX (three thousand per month) is a
third party publisher of news and research .Our sites do not make recommendations, but offer
information portals to research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy or sell products or securities. This site
is currently compensated by featured companies, news submissions and online advertising. Disclaimer: Disclosure:

Source:, BioSante,
Contact to become a biotech showcase stock or research biotech stocks
800 665 0411

No comments:

Post a Comment